ArticleGastro hep advances2022
Fibrosis-3 Index: A New Score to Predict Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Without Age as a Factor.
Article in Gastro hep advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07791589 (Fibrosis Versus Metabolic Risk in MASLD), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fibrosis Versus Metabolic Risk in MASLD: Age-Adjusted Associations With PREVENT Cardiovascular Risk
Who cites it
17 citing papers in PubMed.
- Article
- Clinical utility of the MAF-5 score for assessing MAFLD/MASLD in a Japanese population with obesity.Diabetology international · 2026Article
- Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention.Clinical and experimental hepatology · 2025Article
- Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds.Journal of clinical medicine · 2025Article
- Usefulness of the Fibrosis-3 index in patients with hepatitis C.Annals of medicine and surgery (2012) · 2025Article
- Article
- Impact of the FIB4 Index on Pre-sarcopenia in Patients with Metabolic-dysfunction Associated Steatotic Liver Disease.Internal medicine (Tokyo, Japan) · 2025Article
- A potential age-independent MASLD-related liver fibrosis index based on metabolic profiling.Scientific reports · 2025Article
- FIB-3 index as a novel age-independent predictor of liver fibrosis and prognosis in hepatocellular carcinoma patients undergoing hepatectomy.Annals of gastroenterological surgery · 2025Article
- Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- A Noninvasive Method of Diagnosing Metabolic Dysfunction-Associated Steatohepatitis Using Cytokeratin-18 Fragment and FIB-3 Index.Diagnostics (Basel, Switzerland) · 2025Article
- Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.Journal of gastroenterology · 2025Article
- Article
- Article
- An Alternative Non-Invasive Screening Model for Liver Fibrosis among US Adults at Risk of MASLD.Diseases (Basel, Switzerland) · 2024Article
- Identification of risk groups for advanced liver fibrosis in the general population using the Fibrosis-3 index.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Diagnostic Accuracy of Noninvasive Scores for Fibrotic MASH in a Cohort of Biopsy-proven MASLD Patients With Predominantly High BMI in the Primary Care Setting.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The Fibrosis-4 (FIB-4) index has been used to predict liver fibrosis in various liver diseases, including nonalcoholic fatty liver disease (NAFLD). Because the FIB-4 formula uses age, different cutoff values may be required for different age groups, making the interpretation difficult. To avoid the influence of age, we attempted to create a new score, the Fibrosis-3 (FIB-3) index. Methods: The FIB-3 index was created using a training cohort of 735 NAFLD cases using aspartate aminotransferase, alanine amino transferase, and platelet for predicting fibrosis. The abilities of the FIB-3 and FIB-4 indices were compared among different age groups in the training cohort and validation cohort with 324 patients. The FIB-3 index was also compared with other liver fibrosis indices. Results: The area under the receiver operating characteristic curve (AUROC) values of the FIB-3 and FIB-4 indices for predicting F3-F4 fibrosis were 0.764 and 0.762, respectively, in the training cohort. No difference in the AUROC values was observed between the 2 indices in the validation cohort. The differences in the accuracies of FIB-3 between elderly and nonelderly patients were 0.140 and 0.178, respectively, in each cohort and were smaller than those of FIB-4 index (0.199 and 0.336, respectively). Analysis using a joined cohort revealed that the AUROC of FIB-3 for predicting F3-F4 fibrosis (0.774) was the highest among the 5 fibrosis scores examined and was comparable to that of FIB-4. Conclusion: The FIB-3 index is an improved version of the FIB-4 index and can effectively predict liver fibrosis in patients with NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.